Erickson Living

ericksonliving.com

Erickson Living is the leading developer and manager of continuing care communities and home to 25,000 seniors across the United States. Each day, our 15,000 employees strive to provide the very best in care and service to the residents who choose to call us home. With first rate amenities and programs delivered in vibrant campus settings, Erickson Living is setting a new standard of senior health and wellness.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

news image

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

news image

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More

INDUSTRIAL IMPACT

ABCELLERA AND RALLYBIO ANNOUNCE STRATEGIC ALLIANCE TO DISCOVER, DEVELOP, AND COMMERCIALIZE NOVEL ANTIBODY-BASED THERAPEUTICS FOR RARE DISEASES

Rallybio | December 02, 2022

news image

AbCellera and Rallybio Corporation announced that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients. “It’...

Read More

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories | September 15, 2020

news image

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More
news image

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More
news image

INDUSTRIAL IMPACT

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More
news image

INDUSTRIAL IMPACT

ABCELLERA AND RALLYBIO ANNOUNCE STRATEGIC ALLIANCE TO DISCOVER, DEVELOP, AND COMMERCIALIZE NOVEL ANTIBODY-BASED THERAPEUTICS FOR RARE DISEASES

Rallybio | December 02, 2022

AbCellera and Rallybio Corporation announced that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients. “It’...

Read More
news image

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories | September 15, 2020

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us